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Variceal hemorrhage is one of the major complications of liver cirrhosis associated with signiﬁcant mortality and morbidity. Its
managementhasevolvedoverthepastdecadeandhassubstantiallyreducedtherateofﬁrstandrecurrentbleedingwhiledecreasing
mortality. In general, treatment of esophageal varices can be divided into three categories: primary prophylaxis (prevention of ﬁrst
episode of bleeding), management of acute bleeding, and secondary prophylaxis (prevention of recurrent hemorrhage). The goal
of this paper is to describe the current evidence behind the management of esophageal varices. We will discuss indications for
primary prophylaxis and the diﬀerent modes of therapy, pharmacological and interventional treatment in acute bleeding, and
therapeutic options in preventing recurrent bleeding. The indications for TIPS will also be reviewed including its possible beneﬁts
in acute variceal hemorrhage.
1.Introduction
Portal hypertension in liver cirrhosis results from the ana-
tomical changes and the development of contractile element
in the liver vascular bed secondary to progressive hepatic
ﬁbrosis and formation of regenerative nodules [1, 2]. The
increase in portal pressure triggers splanchnic vasodilation,
increased cardiac output, and ﬂuid/salt retention leading to a
hyperdynamic circulation and increased portal ﬂow. Forma-
tion of collaterals between the portal and systemic systems
suchasthosefoundintheloweresophagusandgastriccardia
(gastroesophageal varices) may not only relieve some of the
pressure, but also pose a risk for rupture and bleeding [2].
The prevalence of gastroesophageal varices ranges from
0–40% in compensated cirrhosis to 70–80% in decompen-
sated liver disease, while their growth and progression occur
at an estimated 7% per year [2, 3] .T h eo n e - y e a rr a t eo fﬁ r s t
variceal hemorrhage is 5% for small varices and 15% for
large varices [4]. Advanced liver disease (Child B or C), large
varices, and varices with red wale marks are bad prognostic
signs associated with higher incidence of bleeding. Six-week
mortality with each episode of bleeding varies between 15
and 20% and is largely dependent on the severity of the liver
disease (0% for Child A and 30% for Child C) [5–7]. Finally,
the 1-year rebleeding rate following initial variceal hem-
orrhage is approximately 60% [8].
The current treatment of gastroesophageal varices has
substantially reduced the rate of ﬁrst and recurrent bleeding
while decreasing the mortality of acute variceal hemorrhage
[9, 10]. The purpose of this paper is to summarize the man-
agementofgastroesophagealvaricesintermsofprimarypro-
phylaxis (prevention of ﬁrst episode of bleeding), treatment
ofacutehemorrhage,andsecondaryprophylaxis(prevention
of recurrent bleeding).
2. PrimaryProphylaxis
Nonselective beta-blockers are the current mainstay of ther-
apyinthepreventionofﬁrstepisodevaricealhemorrhage[9–
11]. β1 inhibition reduces cardiac output while β2-blockade
inducessplanchnicvasoconstrictionandtogetheritresultsin
decreased portal ﬂow and pressure [12]. Nonselective beta-
blockers used for primary prophylaxis in North America
include propranolol and nadolol. Carvedilol has recently2 International Journal of Hepatology
been investigated in portal hypertension given its alpha-
blocking component and its potential to better diminish
portal pressure [13]. However, more data will be needed on
its eﬀectiveness and long-term safety. At this time it is pre-
mature to endorse Carvedilol as a ﬁrst-line agent for primary
prophylaxis. In terms of dosing and goal of treatment, it is
recommended to start at a low dose and to titrate up as toler-
ated until a heart rate of 55 beats/minute is achieved [9–11].
2.1. Cirrhosis with Small Varices. In patients with low-risk
small varices (Child A without red wale marks), the use of
nonselective beta-blocker is optional [9]. There is limited
evidence showing that nonselective beta-blockers may slow
the growth of varices but they do not reduce mortality and
their use cannot be universally recommended over regular
endoscopic surveillance (every 2 years and annually with
hepatic decompensation) [14]. However, nonselective beta-
blockers are recommended in patients with small varices and
high-risk features such as red wale marks and/or Child B-C
cirrhosis [9].
2.2. Cirrhosis with Medium to Large Varices. A large meta-
analysis looking at propranolol/nadolol versus placebo, in
patients with cirrhosis and medium to large varices, found
a signiﬁcantly lower incidence of ﬁrst variceal bleeding in
the treatment group: 14% compared to 30% [4]. Also, these
nonselective beta-blockers may be equivalent to endoscopic
varicealbandligation(EVBL)intermsofprimaryprevention
and mortality rate [15, 16]. In addition, they are inexpensive
and can potentially prevent other complications of cirrhosis
such as spontaneous bacterial peritonitis and bleeding from
portal hypertensive gastropathy [17, 18]. However, 15–
20% of patients treated with nonselective beta-blockers are
noncompliant due to common side eﬀects such as fatigue,
dizziness, and shortness of breath. EVBL is associated with
fewer side eﬀects and does not rely on patient compliance
but requires technical expertise and can lead to serious
complications such as bleeding from ligation-induced ulcers
[12, 19]. Finally, a randomized controlled trial comparing
EVBL and propranolol to EVBL alone in patients with large
varices did not show a diﬀerence in terms of mortality
or incidence of ﬁrst bleed [20]. Therefore, depending on
patient/physician preference and available expertise either
nonselective beta-blocker or EVBL alone should be used
for primary prophylaxis in cirrhosis with medium to large
varices. Combination therapy does not seem to confer any
additional beneﬁt (Table 1).
3.AcuteVariceal Bleeding
The management of acute variceal bleeding with the com-
bination of vasoconstrictors, endoscopic therapy, and anti-
biotics has decreased mortality substantially [9, 10]. Initial
assessment of a patient with acute variceal hemorrhage be-
ginswiththeevaluationofairway,breathing,andcirculation.
Many of these patients are at risk for aspiration and intu-
bation is often performed for airway protection, although
there are limited data to justify this practice [21, 22]. Volume
resuscitation with blood and ﬂuid is essential in the initial
stabilization; however, experimental studies suggest that
overly aggressive volume repletion can worsen bleeding and
increase the rate of rebleeding and mortality [23]. Therefore,
meticulous resuscitation with a target hemoglobin level of
8g/dL is recommended [23, 24]. In addition, animal studies
suggest that blood transfusion may be superior to ﬂuid
administration given that ﬂuid resuscitation may decrease
blood viscosity, which can exacerbate portal pressure and
potentially worsen acute variceal hemorrhage [25]. Correc-
tion of signiﬁcant coagulopathy and thrombocytopenia with
fresh frozen plasma and platelet transfusions should also be
considered [10]. Studies on Factor VIIa have failed to show
beneﬁt in terms of mortality and control of bleeding and its
use is currently not recommended [6].
4.AntibioticsinAcute Variceal Bleeding
Acute variceal hemorrhage has been shown to increase the
risk for severe bacteremia, which is associated with higher
mortality rates and greater incidence of rebleeding [26–
28]. Meta-analyses have revealed that antibiotic prophylaxis
can improve short-term survival while decreasing bacterial
infections and rebleeding rates [26, 29, 30]. Oral norﬂoxacin
or intravenous ciproﬂoxacin for 7-days, administered at the
time of acute bleeding, works by decreasing the amount of
gram-negative bacteria in the gut believed to be the most
common source for infection in cirrhosis [27, 28]. However,
in patients with advanced cirrhosis (Child B/C) ceftriaxone
may be superior to norﬂoxacin in preventing infections
[28]. This is likely due to ceftriaxone’s extended coverage
against nonenterococcal streptococci and quinolone-resist-
ant Gram-negative bacteria. Therefore, cirrhotic patients
without advanced liver insuﬃciency and acute variceal hem-
orrhage should receive either oral norﬂoxacin or IV cipro-
ﬂoxacin for 7 days while ceftriaxone is preferred in patients
with Child B/C cirrhosis or previous quinolone use.
5. Pharmacological Therapy and
Endoscopic Management
In addition to antibiotics, vasoactive agents such as vaso-
pressin, terlipressin, somatostatin, and octreotide play a
major role in controlling acute esophageal variceal hemor-
rhage through their ability to induce splanchnic vasocon-
strictiontherebyreducingportalﬂowandpressure[9,10].In
fact,theymaybeequallyaseﬀectiveasendoscopicsclerother-
apy in controlling initial bleeding and in preventing rebleed-
ing with less adverse eﬀects [31, 32]. These agents, when
administered at the time when variceal bleeding is suspected,
can achieve initial hemostasis in 60–80% of the cases [33].
Vasopressin is a potent vasoconstrictor that reduces
blood ﬂow to all splanchnic organs leading to substantial
decreases in portal pressure [10]. However, its use has been
limited by its side eﬀects such as hypertension, cardiac, and
peripheral ischemia, and ischemic bowel. Terlipressin is a
synthetic analogue of vasopressin with longer pharmacolog-
ical activity and fewer side eﬀects [4, 10, 34]. The intactInternational Journal of Hepatology 3
Table 1: Primary prophylaxis and surveillance.
Surveillance/prophylaxis
modalities Indications Dose Goal
Endoscopic surveillance Low-risk∗ small varices
(not on nonselective BB∗∗)
Every 2 years and
annually with liver
decompensation
Surveillance for progression into
higher-risk lesions needing medical or
endoscopic prophylaxis
Nadolol
High-risk∗∗∗ small varices and
medium-large varices
Optional: low-risk small varices
Start: 40mgqd Titrate to heart rate: 55 beats/minute
or maximally tolerated dose
Propranolol
High-risk small varices and
medium-large varices
Optional: low-risk small varices
Start: 10mgbid Titrate to heart rate: 55 beats/minute
or maximally tolerated dose
EVBL Medium to large varices Every 2–4 weeks Until variceal obliteration
∗Low-risk: Child A cirrhosis and no red wale marks, ∗∗beta-blocker, ∗∗∗high-risk: Child B or C cirrhosis and/or presence of red wale marks.
molecule has immediate vasoconstrictive activity, which is
followed by a delayed eﬀect secondary to a slow enzymatic
breakdown of terlipressin into vasopressin. It is the only
agent that has been demonstrated to decrease mortality
in acute variceal hemorrhage [4]; however, it is not yet
available in North America. In terms of dosing, terlipressin
is given intravenously and should be started at 2mg every
4 hours for 48 hours, followed by 1mg every 4 hours [9].
The optimal duration of treatment is unknown but current
recommendations suggest a total of 2–5 days.
Somatostatin is a naturally occurring tetradecapeptide
that has inhibitory eﬀects on exocrine/endocrine hormones,
gastrointestinal motility, and systemic blood ﬂow leading to
a decreased circulation and pressure in the portal and porto-
collateral system [34]. Octreotide, a synthetic analogue of
somatostatin with greater potency and longer half-life, is
the only substance available in North America mainly due
to its safety proﬁle and its apparent eﬀectiveness when
used in combination with EVBL [9, 34, 35]. However, its
eﬀectiveness in controlling acute variceal hemorrhage has
not been ﬁrmly established [11, 34]. In terms of dosing, it
is administered intravenously and should be initiated with
a 50 mcg bolus followed by an infusion at 50mcg/hr [9]. A
bolus can be repeated in the ﬁrst hour if variceal hemorrhage
is uncontrolled. As with terlipressin therapy should be
continued for 2–5 days (Table 2).
Following initiation of vasoactive agents, EGD should be
performed within 12 hours of presentation [10]. EVBL is
superior to sclerotherapy and is the modality of choice [19].
The combination of EVBL with pharmacological therapy
is the current standard of care and when compared to
EVBL alone it improves initial control of bleeding and 5-day
hemostasis without a mortality beneﬁt [36].
6. Role of TIPS inAcuteVariceal Bleeding
The use of transjugular intrahepatic portosystemic shunt
(TIPS) in acute variceal hemorrhage has been historically
reservedforsalvagetherapyinpatientswhohavefailedendo-
scopic and pharmacological treatment. However, a recent
randomized controlled trial looking at early TIPS, deﬁned as
within 72 hours of standard therapy (EVBL + antibiotic +
vasoactive agent), versus standard therapy alone showed that
in patients with Child B/C cirrhosis the early use of TIPS was
associated with a reduction in the failure to control bleeding,
lower incidence of rebleeding, and decreased mortality rate
[37]. In addition, the TIPS group did not have an increased
incidence of hepatic encephalopathy. Notably, however, the
outcomes in the nonearly TIPS group were unusually poor.
Although more studies will be needed to conﬁrm these
ﬁndings, the early use of TIPS should be considered in
patients with severe liver disease who present with acute
variceal bleeding following initial standard therapy.
7.Secondary Prevention
Patientswhosurviveanepisodeofacutevaricealhemorrhage
are at high risk of recurrence. Overall, 60% of these individ-
uals will rebleed within 2 years with a mortality rate of 33%
[4, 8]. Therapy aimed at reducing this risk is essential and
should be implemented as soon as the initial hemorrhage
is controlled [9, 10]. Multiple modes of treatment have
been investigated including monotherapy with nonselective
beta-blockers, combination medical therapy, EVBL with or
without pharmacological adjunct, and TIPS.
Nonselective beta-blockers have been shown to decrease
rebleeding rates from 60% to 42-43% likely secondary to
the decrease in portal pressure [4, 8, 24]. Further portal
pressure reduction can be achieved when they are combined
withoralnitrates(ISMN)[38].Nitrate-inducedvenodilation
decreases cardiac output and blood pressure, which can
lead to a baroreceptor-mediated splanchnic vasoconstriction
and fall in portal pressure [39]. It may also have a direct
vasodilatory eﬀect on the portosystemic circulation; how-
ever, a randomized trial and a recent meta-analysis did not
show any beneﬁt in adding a nitrate. In addition, combined
therapy is associated with more adverse eﬀects leading to
discontinuation of treatment [40, 41].
In terms of endoscopic therapy, EVBL is superior to scle-
rotherapyandisthemethodofchoice[42,43].Meta-analysis
of several randomized controlled trials (719 patients) com-
paring EVBL versus combination medical therapy, with non-
selective beta-blockers and nitrates, showed no diﬀerence
in rebleeding rate and increased survival in the medically4 International Journal of Hepatology
Table 2: Initial medical management of acute variceal bleeding.
Treatment Dose Duration Details
Antibiotics
Ceftriaxone 1g IV daily 5–7 days Severe cirrhosis Child B/C and/or high suspicion of
quinolone resistance
Ciproﬂoxacin 400mg IV or 500mg oral twice daily 5–7 days Mild cirrhosis Child A and low suspicion of quinolone
resistance
Norﬂoxacin 400mg oral twice daily 5–7days Mild cirrhosis Child A and low suspicion of quinolone
resistance
Vasoconstrictors
Octreotide 50μg IV bolus, then infusion at 50μg/hr 2–5 days Initial bolus can be repeated in the ﬁrst hour if bleed
not controlled
Terlipressin 2mgIVevery4hr× 48hr, then 1mg IV
every 4hr 2–5 days Not available in North America
Somatostatin 250μg IV bolus, then 250–500μg/hr 2–5 days Not available in North America
treated group [44–47] .A l s o ,t w op r o s p e c t i v et r i a l ss u g -
gest that the combination of EVBL with medical therapy
(nadolol) may be superior to EVBL alone [48, 49]. The
use of EVBL and a nonselective beta-blocker is the current
recommendation for secondary prophylaxis and should be
instituted without delay following initial bleed [10]. How-
ever, a recent randomized controlled trial looking at combi-
nation therapy (EVBL + nadolol + nitrate) versus medical
therapy alone (nadolol + nitrate) found no diﬀerence in
rebleeding rates, need for rescue therapy, or mortality while
the combination therapy was associated with more adverse
events [50]. More studies will be needed to conﬁrm these
ﬁndings but future guidelines may move towards medical
therapy alone.
Finally, TIPS in secondary prophylaxis has been shown
to lower rebleeding rates when compared to the afore-
mentioned medical/endoscopic therapy [51–53]. However,
no mortality beneﬁt has been demonstrated with TIPS
and its use is associated with higher costs and incidence
of hepatic encephalopathy. Therefore, the use of TIPS in
secondary prophylaxis is not recommended; however, its
use may be considered following failure with conventional
medical therapy [10]. This may change with the advent of
polytetraﬂuoroethylene- (PTFE-) covered prostheses, which
substantially improves TIPS patency.
Insummary,EVLincombinationwithnonselectivebeta-
blockers is the method of choice in preventing recurrent
variceal bleeding. The addition of nitrates can theoretically
potentiate the portal pressure drop; however, it has not
been shown to decrease mortality or rebleeding rates and
is associated with greater side eﬀects. TIPS is not rec-
ommended for secondary prophylaxis and should only be
considered following failure with usual medical therapy. It
decreases rebleeding rates without a mortality beneﬁt while
being associated with higher costs and incidence of hepatic
encephalopathy. Whether the new PTFE covered stent will
improve TIPS eﬃcacy in secondary prophylaxis remains to
be seen, but forthe moment its use is restricted to those cases
where other therapies have failed.
8. Conclusion
The management of gastroesophageal varices has evolved
over the last decade resulting in improved mortality and
morbidity rates. Primary prevention with nonselective beta-
blockers or EVBL should be initiated in all patients with
medium to large varices and in patients with small varices
associated with high risk features such as red wale marks
and/or advanced cirrhosis. While prophylaxis in patients
with small varices without high risk features is considered
optional. In acute bleeding, vasoactive agents such as octreo-
tide or terlipressin should be initiated along with antibiotics
followed by EVBL within 12 hours of presentation. These
patients are at increase risk for rebleeding and secondary
preventionshouldbeinitiatedimmediatelyfollowingcontrol
of initial hemorrhage with serial EVBL and nonselective
beta-blocker. Currently, TIPS’ role in secondary prophylaxis
is limited except for failure with conventional therapy;
however, this may change with the advent of PTFE covered
stents. Although therapy for patients with varices has made
signiﬁcant progress, it will continue to improve with better
endoscopic technique, novel pharmacological agents, greater
eﬃciency of liver transplant, and more eﬀective rescue ther-
apy.
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